Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan and Toripalimab in Unresectable Stage III NSCLC
NCT06706219Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2026
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoints: 18-month Event-Free Survival rate and Surgical Conversion Rate at 8 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06706219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706219.